Thomas Larssen - Aurora Cannabis President of Aurora Larssen Projects Ltd
| ACB Stock | USD 4.34 0.04 0.93% |
Insider
Thomas Larssen is President of Aurora Larssen Projects Ltd of Aurora Cannabis since 2017.
| Tenure | 7 years |
| Address | 90B Street SW, Edmonton, AB, Canada, T6X 1V8 |
| Phone | 855 279 4652 |
| Web | https://www.auroramj.com |
Aurora Cannabis Management Efficiency
The company has Return on Asset of (0.0124) % which means that on every $100 spent on assets, it lost $0.0124. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0579) %, meaning that it generated no profit with money invested by stockholders. Aurora Cannabis' management efficiency ratios could be used to measure how well Aurora Cannabis manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.07. At present, Aurora Cannabis' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 744.6 M, whereas Total Current Assets are forecasted to decline to about 234.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| FACP MD | Moleculin Biotech | 70 | |
| Sumita JD | Instil Bio | 50 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Louis Ploth | Moleculin Biotech | 70 | |
| MBA MD | Moleculin Biotech | N/A | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Jeffery MD | Bio Path Holdings | N/A | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| MBA BS | CytomX Therapeutics | 45 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Anish MD | Soleno Therapeutics | 54 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Victoria Rac | Bio Path Holdings | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -0.0579 | ||||
| Return On Asset | -0.0124 |
Aurora Cannabis Leadership Team
Elected by the shareholders, the Aurora Cannabis' board of directors comprises two types of representatives: Aurora Cannabis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aurora. The board's role is to monitor Aurora Cannabis' management team and ensure that shareholders' interests are well served. Aurora Cannabis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aurora Cannabis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lori Schick, Executive Resources | ||
| Simona King, Chief Officer | ||
| Alex Miller, Executive Chain | ||
| Darren Karasiuk, Executive Vice President - Adult Usage | ||
| Carey Squires, Executive Vice President of Corporate Development and Strategy | ||
| Michael Singer, Executive Chairman of the Board, Interim Chief Executive Officer | ||
| Jillian Swainson, Chief Legal Officer, Corporate Secretary | ||
| Andre Jerome, Executive Vice President - Global Business Development | ||
| Dave Aird, Executive Technology | ||
| Miguel Martin, Chief Executive Officer, Director | ||
| Nathalie Clark, General VP | ||
| Steve Dobler, President Director | ||
| Adam Szweras, Independent Director | ||
| Jonathan Page, Chief Scientific Officer | ||
| Neil Belot, Chief Global Business Development Officer | ||
| Debra Wilson, Chief Human Resource Officer | ||
| Ananth Krishnan, Vice Relations | ||
| Theresa Firestone, Independent Director | ||
| Lance Friedmann, Independent Director | ||
| David Aird, Executive Technology | ||
| John Barnet, Chief Cultivator | ||
| Margaret Atkins, Independent Director | ||
| Glen Ibbott, Chief Financial Officer | ||
| Michael Detlefsen, Independent Director | ||
| Simona CPA, Chief Officer | ||
| Darryl Vleeming, Chief Information Officer | ||
| Thomas Larssen, President of Aurora Larssen Projects Ltd | ||
| Rick Savone, Senior Vice President - Global Government Relations | ||
| Norma Beauchamp, Independent Director | ||
| Ronald Funk, Independent Chairman of the Board | ||
| Michelle Lefler, Vice Relations | ||
| Allan Cleiren, Chief Operational Officer | ||
| Jason Dyck, Independent Director |
Aurora Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aurora Cannabis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0579 | ||||
| Return On Asset | -0.0124 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 248.95 M | ||||
| Shares Outstanding | 54.88 M | ||||
| Shares Owned By Institutions | 13.06 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | 46.94 X | ||||
| Price To Book | 0.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aurora Cannabis offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurora Cannabis' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurora Cannabis Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurora Cannabis Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurora Cannabis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Aurora Stock refer to our How to Trade Aurora Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurora Cannabis. If investors know Aurora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurora Cannabis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.92) | Earnings Share (0.46) | Revenue Per Share 0.033 | Quarterly Revenue Growth 0.285 | Return On Assets (0.01) |
The market value of Aurora Cannabis is measured differently than its book value, which is the value of Aurora that is recorded on the company's balance sheet. Investors also form their own opinion of Aurora Cannabis' value that differs from its market value or its book value, called intrinsic value, which is Aurora Cannabis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurora Cannabis' market value can be influenced by many factors that don't directly affect Aurora Cannabis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurora Cannabis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurora Cannabis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurora Cannabis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.